Cardiff Oncology Amends Onvansertib License, Resolves LitigationTip Ranks·Sep 14 at 01:47 PMCRDF-3.13%
Cardiff Oncology, Nerviano Medical Sciences expand onvansertib collaboration under amended license agreementPUBT·Sep 14 at 01:28 PMCRDF-3.13%
Cardiff Oncology, Nerviano settle onvansertib rights lawsuit, seek dismissal with prejudicePUBT·Sep 14 at 12:31 PMCRDF-3.13%
Cardiff Oncology (NASDAQ:CRDF) Stock Rating Upgraded by Wall Street ZenMarket Beat·Sep 5 at 05:12 AMCRDF-3.13%RJF+0.70%
Cardiff Oncology to Participate in September 2026 ConferencesUnusual Whales·Sep 2 at 11:08 AMCRDF-3.13%
Localized Expansion Meets Defensive Flows: Structural Signals Across U.S. EquitiesGlobal Report·Aug 25 at 11:33 AMPOWL-1.09%DEFT-5.26%
Under-the-Radar Moves: From NeoVolta's Expansion to Thomson Reuters' AI PushGlobal Report·Aug 25 at 09:21 AMCRDF-3.13%NEOV-8.56%
North American Morning Briefing: Stock Futures Rise Ahead of PPI Inflation Report -2-MorningStar·Aug 13 at 10:31 AMNOA-1.52%CAE+0.97%
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business UpdateUnusual Whales·Aug 11 at 08:13 PMCRDF-3.13%
